Original post: Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial
Original post: Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial
Read the original: Applied Therapeutics Appoints John H. Johnson as Executive Chairman
Excerpt from: Verrica Provides Business and Operational Update
Read more from the original source: ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility
Continued here: Lowell Farms Inc. Appoints Philippe Faraut as Chief Financial Officer
Read more: InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904
Read the original: Sernova Reschedules its Annual General and Special Meeting of Shareholders to January 10, 2025
See the article here: Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets
Read the original here: Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid...
Originally posted here: RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial
Recent Comments